Navigation Links
Monogram Announces 2008 Third Quarter Financial Results
Date:10/27/2008

icer. "While reported gross margin on product revenues for the third quarter was 51%, adjusted for the deferral of $1.6 million in revenues related to our Pfizer collaboration, gross margin would have been 55%."

The Company had approximately $21.8 million in cash and cash equivalents at September 30, 2008. Cash used in operations for the first nine months of 2008 was $13.0 million.

HIV Tropism Testing

"Monogram's enhanced Trofile Assay, introduced earlier this year with a thirty-fold improvement in sensitivity, has allowed a very important new analysis of Pfizer Inc.'s phase III trial of Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic HIV-1, known as the 'MERIT' study," said William Young, Monogram chief executive officer. "Data reported this week by Pfizer demonstrated that in this study, increased efficacy was shown as a result of the enrichment of the patient population by use of the enhanced version of Monogram's Trofile(TM) Assay." Results of the reanalysis of the "MERIT" trial were reported this week at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington DC.

Pfizer's HIV medication Selzentry (maraviroc) is approved for use in treatment-experienced individuals with R5-tropic HIV-1. In July 2007 Pfizer reported data from the phase III trial of Selzentry in treatment naive individuals ("MERIT"), in which patients had been selected for treatment by Monogram's Trofile Assay. The reported differences in outcome for individuals treated with Selzentry did not meet a predefined study endpoint of non-inferiority to an established first line treatment regimen. To week 48, 65% of individuals receiving Selzentry had HIV-1 RNA <50 copies/mL, compared to 69% of those individuals in the control arm of the trial.

In June 2008 Monogram introduced an enhanced sensitivity version of the Trofile Assay, with 30-fold greater sensitivity to detect low-level X4 HIV compared
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  AnaptysBio, Inc., a leader in the ... announced the advancement of its first-in-class anti-interleukin-36 ... The Company,s anti-IL-36R therapeutic antibody, called ANB019, ... psoriasis (GPP), an orphan systemic inflammatory disease ... owned within AnaptysBio,s proprietary antibody pipeline and ...
(Date:4/16/2015)... 16, 2015 Avelas Biosciences, an in ... surgeries, announced today that it has initiated a Phase ... in women with primary, non-recurrent breast cancer undergoing surgery. ... the addition of Steven Chen , M.D., as ... label, dose escalation study will enroll up to 39 ...
(Date:4/16/2015)... , Switzerland , ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ , ... drugs that target unmet medical needs as ... preclinical data on the investigational compounds Debio 1143 ... will be presented at the 2015 Annual ...
(Date:4/16/2015)... NJ (PRWEB) April 16, 2015 ... Dr. Joseph V. Gulfo to become the Executive ... Entrepreneurship. Simultaneously, FDU announced the kick-off of the ... program spearheaded by Dr. Gulfo, under the Rothman ... College of Business) and in collaboration with FDU’s ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... Looking to raise more venture capital for clinical trials, ... at the annual InvestMidwest venture capital forum next ... at the 2006 forum, would like to raise an additional ... trials that are set to begin in early 2008. ...
... the key skills for today's success are flexibility, adaptability, ... in order to compete in the global marketplace. This ... misperception that there is a shortage of highly skilled, ... there are many qualified, highly skilled, technical people here, ...
... ago, I had no idea that I would continue with it ... to share with other members of the Midwest life-science community information ... just overall awareness about life science in the Midwest. , ... I couldn't afford the kind of market research we used to ...
Cached Biology Technology:ZyStor seeks to raise $15M for clinical trials 2ZyStor seeks to raise $15M for clinical trials 3Getting beyond the vortex of corporate mediocrity 2Getting beyond the vortex of corporate mediocrity 3Getting beyond the vortex of corporate mediocrity 4A Midwest life-science odyssey comes full circle 2A Midwest life-science odyssey comes full circle 3A Midwest life-science odyssey comes full circle 4A Midwest life-science odyssey comes full circle 5A Midwest life-science odyssey comes full circle 6A Midwest life-science odyssey comes full circle 7A Midwest life-science odyssey comes full circle 8
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... criminalistics from Brazil, China, Arab Emirates, Spain, USA, Philippines, ... United Nations (UNODC) will meet in Granada next October ... Prokids Scientific Group Meeting. The meeting will ... worldwide database with genetic information of human trafficking victims ...
... , HONG KONG, Oct. 15 /PRNewswire-Asia/ ... software and hardware,products, announces that its Windows Biometric Framework (WBF) ... for both 32 bit and,64 bit Windows 7, a new ... driver is digitally signed by Microsoft and it may be ...
... faculty from more than 40 academic institutions in North ... first annual Undergraduate Research Conference at the Interface of ... Mathematical and Biological Synthesis (NIMBioS). Undergraduates in biology, ... and present posters on topics ranging from modeling diseases ...
Cached Biology News:DNA against traffic in human beings 2Futronic Windows 7 Biometric Framework Driver is Signed by Microsoft 2
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
... The VersArray ChipWriter Pro system with colony-picking ... technology to array DNA, proteins, oligonucleotides, carbohydrates, ... of substrates for microarray applications. This system ... as small as 300 micrometers in diameter ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: